Dina Hafez
Biochemistry, Genetics and Molecular Biology · University of Michigan
Publications
58
Citations
4,631
Est. group size
—
Recurring co-author estimate
Active years
19
Publishing since 2007
Typically publishes in teams of ~22 · 2% small-team papers (≤3 authors) · across 21 venues
- Knowledge, attitude, practice, and barriers among physicians in the Middle East and North Africa region toward influenza vaccination for the high-risk group of patients: a cross-sectional study
Tropical Diseases Travel Medicine and Vaccines · 2025
- Postoperative pain management quality improvement project using Six-Sigma methodology in Alexandria University Students Hospital, Egypt
International Journal of Lean Six Sigma · 2025
- Gastrocolic Fistula Due to Staple Line Leak Following Metabolic Bariatric Surgery: A Systematic Review
Obesity Surgery · 2025
- Analytical validation of a novel comprehensive genomic profiling informed circulating tumor DNA monitoring assay for solid tumors
PLoS ONE · 2024
- Grocery Delivery to Support Individuals With Type 2 Diabetes: Protocol for a Pilot Quality Improvement Program
JMIR Research Protocols · 2024
- Global acceptance and rejection of COVID-19 vaccines: A systematic review and meta-analysis
Journal of Advanced Pharmaceutical Sciences · 2024
- Supplementary Data from Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences
2023
- Data from Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences
2023
- Supplementary Data from Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences
2023
- Supplementary Data from Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences
2023
- Supplementary Data from Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences
2023
- Supplementary Data from Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences
2023
- Supplementary Data from Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences
2023
- Supplementary Data from Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences
2023
- Supplementary Data from Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences
2023
- Figshare×5
- Nature×2
- Current Diabetes Reports×2
- Cancer Research×2
- JAMA Oncology×1
- Kiran Kumar
Biochemistry, Genetics and Molecular Biology · University of Michigan
- David Tallman
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Anthony Scott
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Ashiq Masood
Biochemistry, Genetics and Molecular Biology · Indiana University
- Nilsa C. Ramirez
Biochemistry, Genetics and Molecular Biology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile